Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial

F. Eilber, A. Giuliano, J. Eckardt, K. Patterson, S. Moseley, James E Goodnight Jr

Research output: Contribution to journalArticle

353 Citations (Scopus)

Abstract

To determine the role of chemotherapy in the multi- disciplinary treatment of patients with osteosarcoma, a randomized prospective trial of postoperative adjuvant chemotherapy was begun in 1981. Fifty-nine patients with nonmetastic classic intramedullary osteosarcoma were randomized; 32 received postoperative adjuvant chemotherapy consisting of high-dose mehtotrexate, Adriamycin (Adria Laboratories, Columbus, OH), and BCD (bleomycin, cytoxan, actinomycin D), and 27 patients received no adjuvant chemotherapy. At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free and overall survival in those who received adjuvant chemotherapy. In addition, there was no difference in the <20% disease-free or over-all survival of patients treated in the 1970s who did not receive chemotherapy, as compared with the concurrent nontreatment controls. Therefore, with identical staging procedures, uniform surgical management, and standard pathologic evaluation, postoperative adjuvant chemotherapy definitely improves disease-free and overall survival in patients with osteosarcoma.

Original languageEnglish (US)
Pages (from-to)21-26
Number of pages6
JournalJournal of Clinical Oncology
Volume5
Issue number1
StatePublished - 1987

Fingerprint

Osteosarcoma
Adjuvant Chemotherapy
Disease-Free Survival
Drug Therapy
Bleomycin
Dactinomycin
Doxorubicin
Cyclophosphamide
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Eilber, F., Giuliano, A., Eckardt, J., Patterson, K., Moseley, S., & Goodnight Jr, J. E. (1987). Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. Journal of Clinical Oncology, 5(1), 21-26.

Adjuvant chemotherapy for osteosarcoma : A randomized prospective trial. / Eilber, F.; Giuliano, A.; Eckardt, J.; Patterson, K.; Moseley, S.; Goodnight Jr, James E.

In: Journal of Clinical Oncology, Vol. 5, No. 1, 1987, p. 21-26.

Research output: Contribution to journalArticle

Eilber, F, Giuliano, A, Eckardt, J, Patterson, K, Moseley, S & Goodnight Jr, JE 1987, 'Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial', Journal of Clinical Oncology, vol. 5, no. 1, pp. 21-26.
Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight Jr JE. Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. Journal of Clinical Oncology. 1987;5(1):21-26.
Eilber, F. ; Giuliano, A. ; Eckardt, J. ; Patterson, K. ; Moseley, S. ; Goodnight Jr, James E. / Adjuvant chemotherapy for osteosarcoma : A randomized prospective trial. In: Journal of Clinical Oncology. 1987 ; Vol. 5, No. 1. pp. 21-26.
@article{1db2ca9ec3984122a1466ba66b4ec94a,
title = "Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial",
abstract = "To determine the role of chemotherapy in the multi- disciplinary treatment of patients with osteosarcoma, a randomized prospective trial of postoperative adjuvant chemotherapy was begun in 1981. Fifty-nine patients with nonmetastic classic intramedullary osteosarcoma were randomized; 32 received postoperative adjuvant chemotherapy consisting of high-dose mehtotrexate, Adriamycin (Adria Laboratories, Columbus, OH), and BCD (bleomycin, cytoxan, actinomycin D), and 27 patients received no adjuvant chemotherapy. At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free and overall survival in those who received adjuvant chemotherapy. In addition, there was no difference in the <20{\%} disease-free or over-all survival of patients treated in the 1970s who did not receive chemotherapy, as compared with the concurrent nontreatment controls. Therefore, with identical staging procedures, uniform surgical management, and standard pathologic evaluation, postoperative adjuvant chemotherapy definitely improves disease-free and overall survival in patients with osteosarcoma.",
author = "F. Eilber and A. Giuliano and J. Eckardt and K. Patterson and S. Moseley and {Goodnight Jr}, {James E}",
year = "1987",
language = "English (US)",
volume = "5",
pages = "21--26",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Adjuvant chemotherapy for osteosarcoma

T2 - A randomized prospective trial

AU - Eilber, F.

AU - Giuliano, A.

AU - Eckardt, J.

AU - Patterson, K.

AU - Moseley, S.

AU - Goodnight Jr, James E

PY - 1987

Y1 - 1987

N2 - To determine the role of chemotherapy in the multi- disciplinary treatment of patients with osteosarcoma, a randomized prospective trial of postoperative adjuvant chemotherapy was begun in 1981. Fifty-nine patients with nonmetastic classic intramedullary osteosarcoma were randomized; 32 received postoperative adjuvant chemotherapy consisting of high-dose mehtotrexate, Adriamycin (Adria Laboratories, Columbus, OH), and BCD (bleomycin, cytoxan, actinomycin D), and 27 patients received no adjuvant chemotherapy. At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free and overall survival in those who received adjuvant chemotherapy. In addition, there was no difference in the <20% disease-free or over-all survival of patients treated in the 1970s who did not receive chemotherapy, as compared with the concurrent nontreatment controls. Therefore, with identical staging procedures, uniform surgical management, and standard pathologic evaluation, postoperative adjuvant chemotherapy definitely improves disease-free and overall survival in patients with osteosarcoma.

AB - To determine the role of chemotherapy in the multi- disciplinary treatment of patients with osteosarcoma, a randomized prospective trial of postoperative adjuvant chemotherapy was begun in 1981. Fifty-nine patients with nonmetastic classic intramedullary osteosarcoma were randomized; 32 received postoperative adjuvant chemotherapy consisting of high-dose mehtotrexate, Adriamycin (Adria Laboratories, Columbus, OH), and BCD (bleomycin, cytoxan, actinomycin D), and 27 patients received no adjuvant chemotherapy. At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free and overall survival in those who received adjuvant chemotherapy. In addition, there was no difference in the <20% disease-free or over-all survival of patients treated in the 1970s who did not receive chemotherapy, as compared with the concurrent nontreatment controls. Therefore, with identical staging procedures, uniform surgical management, and standard pathologic evaluation, postoperative adjuvant chemotherapy definitely improves disease-free and overall survival in patients with osteosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0023125939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023125939&partnerID=8YFLogxK

M3 - Article

C2 - 3543236

AN - SCOPUS:0023125939

VL - 5

SP - 21

EP - 26

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -